Devyn Smith, Arbor Biotechnologies CEO
May 7, 2024 07:00 AM EDTUpdated 02:02 PM
Deals
R&D
Law

Ex­clu­sive: Feng Zhang CRISPR start­up gath­ers patents, lock­ing up rights to fam­i­ly of edit­ing tech

Ryan Cross

Senior Science Correspondent

In the bid to lock up patent rights to a grow­ing suite of gene edit­ing tech­nolo­gies, Ar­bor Biotech­nolo­gies has ac­quired a small start­up found­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

Roche says it is un­de­terred by up­com­ing biosim­i­lar threat to Vabysmo

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times